Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat, Tamoxifen and Pembrolizumab in Advanced Breast Cancer
NCT02395627Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- May 2015
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat, pembrolizumab in breast cancer, sponsored by University of California, San Francisco. Started May 2015; status: terminated.
02
Drugs
vorinostatpembrolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02395627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395627.